外科理论与实践2024，Vol.29Issue(2)：106-113,8.DOI:10.16139/j.1007-9610.2024.02.03
肝细胞癌的转化治疗中几个重要却尚无答案的问题
Conversion therapy of hepatocellular carcinoma:some pivotal issues to be resolved
摘要
Abstract
Progress in the systemic therapies,represented by the molecular target therapies and immune checkpoint inhibitors(ICIs),have significantly improved the prognosis of unresectable hepatocellular carcinoma(uHCC),but long term survial remains limitted.As one of the major combination of systemic and surgical therapies,conversion therapy provides potentially curative opportunity to some uHCC patients.It is widely reported from different domestic centers.The first Chinese expert consensus about it was released in 2021.Yet at the same time,there are many key issues in the practice and theory remains to be resolved.Actively thinking,exploring and finally resolving these issues are essential for establishing and promoting the standardized theoretical system of uHCC conversion therapy.关键词
肝细胞癌/转化治疗/靶向治疗/免疫检查点抑制剂/系统性治疗/手术切除Key words
Hepatocellular carcinoma/Conversion therapy/Target therapy/Immune checkpoint inhibitor(ICI)/Systemic therapy/Surgical resection分类
医药卫生引用本文复制引用
赵磊,钟敬涛,孙惠川..肝细胞癌的转化治疗中几个重要却尚无答案的问题[J].外科理论与实践,2024,29(2):106-113,8.基金项目
山东省重点与研发计划重特大疾病"防诊控治康"科技示范工程(2021SFGC0501) （2021SFGC0501）
